NF2 and schwannoma: The increased sensitivity of Merlin-deficient tumours to MLN3651 also suggests that it could be effective in other tumours in which there are inactivating Merlin mutations, such as schwannoma, ependymoma, mesothelioma, glioma and hepatocellular carcinoma [27,28,29].